pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Antibody-Drug Conjugate (ADC) · news · pharmadog
← back to Antibody-Drug Conjugate (ADC)
News · Antibody-Drug Conjugate (ADC)
230
stories
Jul 16, 26
Spurred by deep cuts and M&A activity, H1 layoffs could oust 14,000+ in biopharma
biospace
Jul 15, 26
Merck ADC, in China study, shows potential to replace chemo in lung cancer
biopharma dive
Jul 15, 26
Kelun’s Merck-partnered ADC notches late-stage NSCLC win alongside Keytruda
biospace
Jul 10, 26
GSK, Hansoh ADC extends survival in lung cancer study
biopharma dive
Jul 10, 26
Hansoh meets Phase 3 SCLC goal; FDA approves Sanofi on-body injector
endpoints
Jul 6, 26
Novartis to acquire ADC developer in a deal worth up to $1.5B
biopharma dive
Jul 6, 26
Novartis commits $1.1B upfront to take Myricx Bio and its next-gen ADC platform
endpoints
Jun 9, 26
Merck, Gilead report mixed outcomes in key lung cancer, HIV studies
biopharma dive
Jun 8, 26
J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for $1B
biopharma dive
Jun 5, 26
Innovent declares Phase 3 success for ADC that attracted huge Takeda deal
endpoints
Jun 4, 26
An ADC specialist sinks on safety concerns for blood cancer drug
biopharma dive
Jun 4, 26
ADC Therapeutics' confirmatory data for Zynlonta muddied by death rates
endpoints
Jun 4, 26
ADC biotech Ona Therapeutics secures $86.6M in Series B raise
endpoints
Jun 4, 26
A Spanish biotech banks $87M to make differentiated ADCs
biopharma dive
May 29, 26
At ASCO, Merck makes case for a ‘cornerstone’ cancer drug
biopharma dive
May 29, 26
Allogene CEO to step down; Agios drug fails key test
biopharma dive
May 28, 26
AbbVie clinches FDA approval for ultra-rare blood cancer ADC from ImmunoGen purchase
endpoints
May 18, 26
Merck ADC, licensed from China, hits mark in first big global trial
biopharma dive
May 18, 26
Merck's ADC sac-TMT gets its first global Phase 3 win ahead of schedule
endpoints
May 14, 26
Emerging Biomarkers in NSCLC: TROP2 Scoring and MTAP Loss
onclive
May 13, 26
Dr Loghavi on the Significance of Updated WHO Diagnostic Criteria for AML in Clinical Practice
onclive
May 13, 26
FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AML
onclive
May 13, 26
FDA Approves Sonrotoclax for Relapsed/Refractory Mantle Cell Lymphoma
onclive
May 13, 26
Dr Dinardo on the FDA Approval of Decitabine/Cedazuridine Plus Venetoclax in AML
onclive
May 13, 26
Future Directions in Metastatic Castration-Resistant Prostate Cancer
onclive
May 13, 26
Personalized Treatment Decision-Making in Metastatic Castration-Resistant Prostate Cancer
onclive
May 13, 26
Future Radiopharmaceutical Strategies in Metastatic Castration-Resistant Prostate Cancer
onclive
May 13, 26
Safety and Toxicity Management in Metastatic Castration-Resistant Prostate Cancer
onclive
May 13, 26
Combination and Sequencing Strategies in Metastatic Castration-Resistant Prostate Cancer
onclive
May 13, 26
Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer
onclive
← prev
page 5 of 8
next →